Insulin resistance drives hepatic de Novo lipogenesis in nonalcoholic fatty liver disease
It is co-expressed in various tissues with mitochondria, and found in plasma, though its levels decline with age
Obesity and excess weight can lead to serious health issues, including heart disease, stroke, diabetes, and even death
Wegovy clinical studies and reported hair loss percentages Wegovy clinical trials show more notable results: Hair loss affected 3% of adult participants compared to 1% in the placebo group [7] The numbers were higher in children 12 and older, where 4% reported hair loss while the placebo group showed no cases [8] Comparing hair loss rates across different GLP-1 medications GLP-1 medications of all types show distinct patterns: Tirzepatide (Mounjaro): Users reported hair loss rates between 4.9% to 5.7% at doses from 5mg to 15mg [8] Zepbound: The overall rates reached 4% to 5%, with women showing much higher numbers 7.1% compared to just 0.5% in men [8] Research from the University of British Columbia shows that people who use semaglutide have a 52% higher chance of hair loss compared to those taking older weight loss medications [9]
This usually improves within a few weeks
Alternatively, they could buy an ETF specialized in weight loss like the Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS)